全文获取类型
收费全文 | 802418篇 |
免费 | 55937篇 |
国内免费 | 1659篇 |
专业分类
耳鼻咽喉 | 10241篇 |
儿科学 | 25649篇 |
妇产科学 | 19070篇 |
基础医学 | 123865篇 |
口腔科学 | 22056篇 |
临床医学 | 73745篇 |
内科学 | 154688篇 |
皮肤病学 | 17843篇 |
神经病学 | 59797篇 |
特种医学 | 29667篇 |
外国民族医学 | 81篇 |
外科学 | 118291篇 |
综合类 | 16001篇 |
现状与发展 | 2篇 |
一般理论 | 230篇 |
预防医学 | 58964篇 |
眼科学 | 17957篇 |
药学 | 60539篇 |
3篇 | |
中国医学 | 2465篇 |
肿瘤学 | 48860篇 |
出版年
2021年 | 7450篇 |
2019年 | 7316篇 |
2018年 | 10142篇 |
2017年 | 7821篇 |
2016年 | 8837篇 |
2015年 | 9909篇 |
2014年 | 13379篇 |
2013年 | 19456篇 |
2012年 | 26792篇 |
2011年 | 27842篇 |
2010年 | 16503篇 |
2009年 | 15377篇 |
2008年 | 25634篇 |
2007年 | 27650篇 |
2006年 | 27575篇 |
2005年 | 26020篇 |
2004年 | 25266篇 |
2003年 | 23639篇 |
2002年 | 23074篇 |
2001年 | 37972篇 |
2000年 | 38431篇 |
1999年 | 31835篇 |
1998年 | 9024篇 |
1997年 | 7611篇 |
1996年 | 7732篇 |
1995年 | 7389篇 |
1994年 | 6742篇 |
1993年 | 6184篇 |
1992年 | 23991篇 |
1991年 | 23874篇 |
1990年 | 23216篇 |
1989年 | 22949篇 |
1988年 | 20818篇 |
1987年 | 20138篇 |
1986年 | 19191篇 |
1985年 | 18045篇 |
1984年 | 13307篇 |
1983年 | 11271篇 |
1982年 | 6434篇 |
1979年 | 11989篇 |
1978年 | 8516篇 |
1977年 | 7172篇 |
1976年 | 6865篇 |
1975年 | 7579篇 |
1974年 | 8834篇 |
1973年 | 8461篇 |
1972年 | 7952篇 |
1971年 | 7363篇 |
1970年 | 7132篇 |
1969年 | 6555篇 |
排序方式: 共有10000条查询结果,搜索用时 11 毫秒
31.
Zusammenfassung Viele gastrointestinale Tumoren werden im Rahmen multimodaler Therapiekonzepte behandelt. Für den Chirurgen ist die neoadjuvante, präoperative Behandlung von besonderem Interesse, da sie durch therapiebedingte Nebenwirkungen und Komplikationen zu einer Beeinflussung des postoperativen Verlaufs führen kann. Die neoadjuvante Radiochemotherapie ist fester Bestandteil der Therapie beim primären T4-Rektumkarzinom, beim Rektumkarzinomrezidiv und bei tief sitzenden primären Rektumkarzinomen. Durch Erhöhung der R0-Resektionsrate können die lokale Tumorkontrolle verbessert und die Überlebenszeit verlängert werden. Die postoperative Komplikationsrate ist dabei nicht wesentlich erhöht. In der Behandlung des primär resektablen Ösophaguskarzinoms deutet sich ein Vorteil der neoadjuvanten Radiochemotherapie im Vergleich zur alleinigen Chirurgie an. Beim lokal fortgeschrittenen Ösophaguskarzinom bietet die präoperative Radiochemotherapie häufig die einzige Chance zur Resektion, jedoch mit einer deutlich erhöhten postoperativen Morbidität und Mortalität. Die Wirksamkeit und Sicherheit einer neoadjuvanten Chemo- oder kombinierten Radiochemotherapie beim fortgeschrittenen Magenkarzinom wird derzeit im Rahmen von Studienprotokollen untersucht. 相似文献
32.
Published data devoted to making and characterization of the properties of polymeric wound dressings with proteolytic action
are reviewed. These data are indicative of individual dependence of the physicochemical properties, activity, and stability
of each particular enzyme on the type of polymer matrix and the method of immobilization. In order to obtain wound dressings,
which are active in physiological medium and retain their activity upon sterilization, it is necessary to optimize the composition
and characteristics of a polymer matrix and the enzyme included into its structure.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 8, pp. 24–28, August, 2006. 相似文献
33.
R H Green C E Brightling S McKenna B Hargadon N Neale D Parker C Ruse I P Hall I D Pavord 《The European respiratory journal》2006,27(6):1144-1151
There is increasing evidence that the assessment of eosinophilic airway inflammation using induced sputum and measurement of airway hyperresponsiveness provides additional, clinically important information concerning asthma control. The aim of this study was to directly compare the effects of different treatments on these markers in patients with asthma and persistent symptoms, despite the use of low-dose inhaled corticosteroids. A double-blind four-way crossover study was performed, which compared a 1-month treatment with budesonide 400 mug b.i.d., additional formoterol, additional montelukast and placebo in 49 patients with uncontrolled asthma despite budesonide 100 mug b.i.d., with each treatment separated by a 4-week washout period. The change in sputum eosinophil count with formoterol (2.4 to 3.8% change, 0.6-fold reduction, 95% confidence interval (CI) 0.5-0.9) differed significantly from placebo (2.8 to 2.5% change, 1.1-fold reduction, 95% CI 0.7-1.6) and high-dose budesonide (2.7 to 1.6% change, 1.6-fold reduction, 95% CI 1.2-2.2). The effects of montelukast did not differ from placebo. The changes in methacholine airway responsiveness were small and did not differ between treatments. High-dose budesonide had the broadest range of beneficial effects on other outcomes, including symptom scores, morning peak expiratory flow and forced expiratory volume in one second. In conclusion, treatment given in addition to low-dose inhaled corticosteroids results in modest benefits. Formoterol and high-dose budesonide have contrasting effects on eosinophilic airway inflammation. 相似文献
34.
N B Pride 《The European respiratory journal》2006,27(1):240-1; author reply 241-2
35.
36.
37.
38.
S Aquilina† M Dalmas‡ N Calleja§ P Gatt† L Scerri† 《Journal of the European Academy of Dermatology and Venereology》2006,20(8):958-963
BACKGROUND: The incidence of malignant melanoma of the skin has risen in every part of the world where reliable cancer registration data are found. OBJECTIVE: Our study aims to describe the changing incidence of and survival from invasive cutaneous malignant melanoma in Malta, by analysing the data from the 211 cases that were registered at the Malta National Cancer Registry between 1993 and 2002. RESULTS: The age standardized incidence rates for invasive cutaneous malignant melanoma rose from 3.7 per 100,000 population per year for males and 5.1 for females in the first 5-year period, to 8.0 per 100,000 population per year for males and 5.9 for females in the second 5-year period. In both sexes, numbers of thin (< or = 1.0 mm) invasive melanomas increased significantly between 1993 and 2002; males also registered a significant increase in intermediate-thickness (1.01-4.0 mm) melanomas. The increase in numbers of thin and intermediate-thickness melanomas between the two 5-year periods was greatest in patients aged 60 years and over. The overall absolute 5-year survival rate for the first period was 74% and for the second period 92%. CONCLUSION: Numbers of reported cases of invasive cutaneous malignant melanoma in Malta have more than doubled during the 10-year study period. This is mostly due to a marked rise in the diagnosis of thin melanomas in both sexes, occurring mainly in patients aged 60 years and over. As thin melanomas are of low metastasizing potential, this has resulted in an increase in survival between the two 5-year study periods. 相似文献
39.
40.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献